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Sabb et al., 2008), and intermediate phenotype (Meyer-Lindenberg 
and Weinberger, 2006; Insel and Cuthbert, 2009) facilitate the same 
basic strategy for optimal reductionism of diagnostic phenotypes. 
An endophenotype can be defined as an internal construct that 
cannot be observed with unaided eyes but can fill the gap between 
clinical symptoms and syndromes on the one end and putative 
genes on the other of a causal chain (Gottesman and Gould, 2003; 
Hasler et al., 2006). Potential endophenotypes should fulfill sev-
eral criteria such as association with the illness in the population, 
substantial heritability, state- independence (with exceptions), 
familial association, co-segregation, and reliability and validity of 
measurement (Chen and Faraone, 2000; Cornblatt and Malhotra, 
2001; Gottesman and Gould, 2003; Chan and Gottesman, 2008). 
The endophenotype strategy (Ritsner, 2009) has greatly increased 
statistical power as it legitimizes the use of unaffected close relatives 
as logical extensions of the study of probands only.
With the completion of the human genome project, the main 
hurdle for biomedical science in this post-genomic era is how to 
characterize the manifold human “endophenotypes” from the 
molecular level to the mind level, and most importantly, detect-
ing “unharmonious minds” in psychiatric disorders (Freimer and 
Sabatti, 2003; Meyer-Lindenberg and Weinberger, 2006; Glahn et al., 
2007; Sabb et al., 2008). The development of cognitive neurosciences, 
neuropsychology and imaging genetics – a strategy for mapping 
neural structure and activity as a function of genotype in humans 
– has encouraged a conceptual transformation by showing that the 
greater power of endophenotypes lies in using genetic risk variants 
in the clinically unaffected relatives of cases as tools for the discovery 
of the mediating neural mechanisms that bridge the gap from DNA 
IntroductIon
The identification of genes with large effects (odds ratios > 1.5) that 
contribute to susceptibilities to neuropsychiatric disorders such as 
schizophrenia and bipolar disorder has progressed to genome-wide 
association studies (GWAS) of large samples. Despite this technolog-
ical advance, the numbers of confirmed loci have remained remark-
ably small, explaining little of the substantial heritabilities of these 
disorders (International Schizophrenia Consortium et al., 2009; Shi 
et al., 2009). This mirrors the state of affairs for type 2 diabetes 
(Zeggini et al., 2008; Panoutsopoulou and Zeggini, 2009) and other 
complex diseases or traits (Manolio et al., 2009). One problem of 
the current approaches is the complete reliance on clinical diagnosis 
as a sufficient phenotype to pursue, which does not allow us to use 
subclinical phenotypic information or endophenotypic informa-
tion (Gottesman and Gould, 2003) which may be informative for 
identifying carriers of vulnerable genotypes. Psychiatric diagnoses 
may represent the joint effects of multiple neurocognitive and 
psychosocial processes, which in turn are partially determined by 
genetic polymorphisms in susceptibility genes. A promising research 
direction is the identification of neurobiological or neurobehavioral 
characteristics that underlie neuropsychiatric disorders, and to find 
genetic polymorphisms that determine susceptibility to the disor-
ders through their effects on these characteristics.
The concept of endophenotype for psychopathology was first 
introduced by Gottesman and Shields (1972, 1973) and has received 
significant interest after a re-conceptualization in 2003 (Gottesman 
and Gould, 2003). Related terminologies to present this construct, 
such as target features (Tsuang et al., 1991; Faraone et al., 1999), 
phenomes (Mahner and Kary, 1997; Freimer and Sabatti, 2003; 
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sequence to pathological behavior. The use of electrophysiology, 
neurochemistry, and neuropsychology can also be powerful tools to 
index intermediate neurobiological processes that are influenced by 
genetic variation and epigenetic processes (Petronis, 2010).
trends In developed countrIes
The completion of genome sequencing does not mean we can grasp 
a more holistic picture about the etiologies of different neuropsy-
chiatric disorders as the study of these disorders is complicated by 
the polymorphisms of the diseases, the impact of environment, 
including G × E interactions (Ge et al., 1996; Plomin et al., 2008) and 
variable phenotypic manifestations related to developmental stages 
and epigenetic (Ptak and Petronis, 2008; Kaminsky et al., 2009; 
Savitz and Drevets, 2009). We are still unable to specify precisely 
the phenotypes (the observed manifestation of the genotypes such 
as symptoms observed in psychiatric patients) in those individuals 
whose genomes we investigate. We continue to depend mainly on 
standard psychiatric disease diagnoses, which are both incomplete 
and imprecise, as representations of human phenotypes.
Most of the findings in this field so far are reported from Western 
countries with several sites doing relevant work. The International 
human phenome project (HPP) (e.g., Freimer and Sabatti, 2003) 
and the International Consortium for Brain Mapping (ICBM) 
(Mazziotta et al., 2001) are international networks that merged 
worldwide data to characterize phenotypes. In particular, the 
HPP is aimed at providing all levels of phenomic information in 
understanding the diagnoses of human diseases, whereas the ICBM 
is focused on brain structure and morphological information in 
human brain. These two projects are too broad and general so that 
it is not specifically designed for neuropsychiatric disorders. Direct 
and time-consuming assessments by experts with new tools will 
probably be essential for collecting most human phenotypic data, 
especially at this stage of their infancy.
The following consortia or networks are more specifically estab-
lished for seven neuropsychiatric disorders. The first is a strong 
network developed at University of California at San Diego with col-
laborating universities, known as the Consortium on the Genetics of 
Schizophrenia (COGS) (Greenwood et al., 2007; Braff et al., 2008). It is 
the pioneering project initiated by the NIMH and aimed at establish-
ing a multisite database to understand the genetic basis of candidate 
endophenotypes for schizophrenia. The COGS focuses on neuro-
physiological (e.g., prepulse inhibition, oculomotor antisaccade) and 
neurocognitive endophenotypes from the U Penn Computerized 
Neurocognitive Battery, Verbal working memory (LNS) and verbal 
memory (CVLT) and continuous performances test (Braff et al., 
2007; Calkins et al., 2007). They are also performing candidate gene 
analyses, developing novel statistical genetics approaches, and other 
methods development. The COGS database is also a resource for 
other emerging strategies (epigenetics and CNV-based studies). 
Moreover, they have built up their network for about 7–8 years and 
have collected several hundred family units (schizophrenic patients, 
non-psychotic probands, parents) and parallel healthy controls from 
the community. Moreover, there is an independent database similar 
to the COGS network by Raquel Gur (Gur et al., 2007). It is more 
focused in nature by reaching consensus on the most promising traits 
and concentrates on these, to achieve larger sample sizes and more 
detailed information across multi-generational families.
A related organization is the MATRICS Psychometric Study 
initiated by the NIMH and contracted out to the University of 
California at Los Angeles. Although their original aim was to refine 
a set of standard psychometric tests or tools suitable for schizophre-
nia research, their refinement of the tools paves a crucial impact on 
the selection of potential cognitive endophenotypes for schizophre-
nia. However, this type of initiative was limited to laboratory-based 
level of measurement and is relatively difficult to articulate to real 
life scenarios and functional outcome directly. Most recently, The 
CNTRICS initiative (R13MH078710) is now being conducted to 
specifically develop new cognitive neuroscience/translational tasks 
for drug development and discovery. For example, tests that were 
deemed well-established and “mature” (mismatching negativity and 
prepulse inhibition) are not part of CNTRICS. This project attempts 
to draw consensus about the phenotypes or endophenotypes that 
are most valuable for schizophrenia treatment research.
Another consortium is specifically examining the cognitive 
phenotype of psychiatric diseases, namely cognitive phenom-
ics, located in the University of California at Los Angeles (Sabb 
et al., 2008). Their main aim is specifically designed to traverse 
multiple disorders, and multiple species to gain traction on phe-
notypes important to mental disorder and their treatment. Such 
an approach has two more additional merits for studying neu-
ropsychiatric disorders endophenotypes. First, it bridges the gap 
between microscopic (e.g., synaptic and molecular abnormalities) 
and macroscopic (e.g., clinical syndromes observed in schizophre-
nia and bipolar disorders) knowledge. Second, unlike the COGS, 
the cognitive phenomics database targets a wider scope of neu-
ropsychiatric disorders in addition to schizophrenia spectrum dis-
orders. Therefore, such an approach may stimulate further similar 
projects or databases that enable broadly collaborative knowledge-
building and translational research. Several other related centers 
or programs have been set up in European countries and Australia 
providing comprehensive repositories for phenotype data that can 
be used on a genome-wide scale for animal and human study (e.g., 
Mouse Phenome Database1; Australian Phenomics Centre2, c.f. 
Freimer and Sabatti (2003).
One additional issue is that new databases are rapidly being devel-
oped to represent gene expression and proteomic knowledge on psy-
chiatric disorders. For example, SchizophreniaGene (SzGene) has 
been developed by Lars Bertram and colleagues formerly at Harvard 
Medical School and Massachusetts General Hospital (now in Berlin) 
to collect and synthesize systematically the genetic data published in 
peer-reviewed scientific journals. For variants (or polymorphisms) 
with published genotypes in at least four independent case–control 
studies, the Bertram team has also systematically meta-analyzed the 
available data in an effort to tease out the most promising schizophre-
nia candidate genes. SzGene currently lists 43 top genes, changing 
monthly, which include candidate genes involved in dopaminergic 
neurotransmission (e.g., DRD1, DRD2, DRD4, COMT), genes dis-
covered by fine-mapping of linkage hot-spots (e.g., NRG1, DAOA, 
DISC1), as well as genes identified by GWAS (e.g., ZFN804A, 
NOTCH4, RELN, NRGN). A promising newcomer is now released 
from the Laboratory of Patrick F. Sullivan at the University of North 
1www.jax.org/phenome
2www.apf.edu.au
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and finally (3) a national/centralized twin registry data (healthy and 
clinical cohorts) [our co-author, the late Professor Ge has already 
registered more than 2,000 pairs in Beijing].
In summary, our team is optimistic about establishing a databank 
for endophenotypes in mainland China, and invites collaborators to 
share in the merits and promise of a potentially useful database on 
phenotypes and endophenotypes for China. This initiative focuses 
on specific cognitive endophenotypes, e.g., neurological soft signs, 
which have been emerged in recent literature as important to mul-
tiple neuropsychiatric syndromes such as schizophrenia, bipolar 
disorders, ADHD, and dementia, but not yet included in the COGS. 
These neurological soft signs may not be specific to schizophre-
nia but also are found in other neuropsychiatric disorders such as 
ADHD (Casey et al., 1997; Sergeant et al., 1999; Chan et al.,2010), 
and major depression (Baldwin et al., 2005), bipolar disorders 
(Mukherjee and Shukla, 1984; Negash et al., 2004); therefore, the 
database may be applicable and extended to a wider range of clinical 
cases with greater public health impact.
conclusIons
Despite the promising and systematic work initiated by our western 
counterparts, there are still a number of caveats for such research 
programs. First, the technology needed to reliably acquire neu-
rophysiological and neurocognitive phenotypes is complex and 
must be carefully adapted to large multisite-population studies. 
The COGS group and other subgroups may not be able to col-
lect a huge amount of targeted families and subjects in a short 
period of time. The use of endophenotypes for genetic studies of 
the aforementioned kind requires large family and patient samples 
and multisite collaborations to achieve sufficient statistical power. 
China is a country with 1.3 billion persons, about 68.7% were in the 
age range of 15–59 years old (National Bureau of Statistics of China, 
2001). One percent (the lifetime prevalence rate of schizophrenia) 
has already accounted for a large sub-population of affected par-
ticipants. Such a large potential sample source complements other 
existing programs and initiatives.
Second, although heritability and familial patterns, as well as 
animal models, provide some evidence for whether or not an endo-
phenotype reflects important genetic effects, identifying a plausible 
causative gene through GWAS (association studies and proteomics) 
is the only definitive answer to that question. The GOGS group in 
the United States takes two approaches to remediate such limita-
tions: (1) determine the segregation and co-segregation of these 
phenotypes and families; (2) perform linkage analysis on those 
phenotypes that appear to show genetic transmission. The results 
of family studies help identify the genetic aspects of schizophre-
nia from physiological and cognitive perspectives, and they may 
also determine which of the various pathophysiological features 
of schizophrenia have a common genetic basis. The results of the 
linkage studies ultimately will be used in subsequent projects to 
identify candidate genes, supported by both linkage and neuro-
biological findings, for molecular sequencing. Moreover, the next 
generation of COGS (i.e., COGS-2) is a case–control design and 
no longer relies on families. Given the known uniqueness of genes 
in different ethnic groups and the interaction effects with rele-
vant environments, the findings from the Western groups should 
complement and expand the findings from a non-western culture 
Carolina, Chapel Hill, known as the Sullivan Lab Evidence Project 
(SLEP) (Konneker et al., 2008) and is bound to attract attention 
and trials. SLEP is a searchable archive of findings from psychiatric 
genetics that is freely available on the web3. Through this searchable 
archive, researchers can access and retrieve data concerning genome-
wide linkage, genome-wide association, and microarray studies for 
a wide range of neuropsychiatric disorders such as ADHD, autism, 
bipolar disorder, easting disorders, major depression, alcohol and 
nicotine dependence, and schizophrenia.
the sItuatIon and Future roadmap In chIna
There is no systematic and comprehensive study of endophenotypes 
for neuropsychiatric disorders in China. There are several sites doing 
specialized work scattered in different places across the country. The 
Bio-X Life Science Research Centre of Shanghai Jiao Tong University 
has been conducting a wide range of genotyping in schizophrenia 
spectrum disorders. The Chinese National Human Genome Centre 
of Beijing and the Institute of Bioinformatics of Tsinghua University 
in Beijing have established a database for schizophrenia candidate 
genes focusing on variations. The State Key Laboratory of Brain and 
Cognitive Science of the Chinese Academy of Sciences in Beijing has 
mainly focused on the underlying cognitive processing of healthy 
people, using imaging technologies. The Key Laboratory of Mental 
Health of the Institute of Psychology of the Chinese Academy of 
Sciences takes an active role in studying the neurocognitive endophe-
notypes for neuropsychiatric disorders such as schizophrenia, bipolar 
disorders and attention deficit, and hyperactivity disorders. There are 
also several other institutes e.g., Chengdu, Nanjing, and Changsha 
that have been contributing to furthering knowledge about genetic 
and cognitive processes of neuropsychiatric disorders.
Although we are somewhat behind our western counterparts 
in this approach, we still stand to make an important and per-
haps unique contribution if we can develop a systematic project in 
China. This program would, in principle, highlight the brain struc-
ture, functional connectivity, and neurocognitive function as well 
as neurological manifestations in the patients and their relatives, 
non-psychotic probands, and healthy controls. In so doing, we will 
bridge the big gap between molecular gene levels and macroscopic 
human mind levels.
The database should have at least two main features. First, data 
that are common to the western samples of databases are less sub-
ject to cultural variation in China, i.e., the supposedly universal 
basic cognition such as sustained attention, working memory, and 
inhibitory control. Second, data that are unique to the Chinese 
population and are more culturally relevant to the Chinese set-
ting, i.e., the supposedly culturally specific social cognitions such 
as emotion perception and expression, e.g., reading text vertically, 
early motoric coordination from use of chopsticks. These data will 
be useful for data merging and cultural comparison. Given these 
considerations, we propose the establishment of the Consortium 
on Human Information and Neurocognitive Endophenotypes 
(CHINE) in China. The CHINE should be composed of three 
main parts, namely (1) neurocognitive, social cognition, and 
 neurophysiological functions (including ERP, structural, and func-
tional  imaging); (2) behavioral genetics and genomic sequencing, 
3http://slep.unc.edu
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can function as an important resource for the policy makers and 
stakeholders to use in planning for future treatment regimes and 
related mental healthy policy.
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like the Chinese. The identification of overlapping versus distinct 
genetically linked features of neuropsychiatric disorders such as 
schizophrenia is a crucial step in the search for targets for interven-
tion as well as validation/prioritization and continued refinements 
of biomarkers/endophenotype-based approaches.
 In conclusion, after reviewing the pros and cons, we suggest a 
clear rationale for the establishment of a consortium for the study 
of endophenotypes in China. Such a consortium – CHINE – will 
be sufficiently large to function as a separate but complemen-
tary entity. In contrast to many developed countries, we strongly 
believe that establishment of such a geographical, cultural, and 
genetically homogeneous consortium can be more focused on its 
own cultural characteristics although it is obviously desirable that 
there is close communication with other consortia so as to iden-
tify those aspects of neuropsychiatric disease that are universal in 
the gene-to-behaviors-pathways. We hope that such a consortium 
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